Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019029 · ClinicalTrials.gov registry record · Phase 1
Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03019029: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03019029 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03019029, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.
Primary Outcome
Standardized uptake value (SUV)
Interventions
- OTHER 18-F Florbetapir PET/MR scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-03-13 |
| Est. Completion | 2022-03-24 |
| Phase | Phase 1 |
What the finished NCT03019029 record still lists
NCT03019029 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which 18-F Florbetapir PET/MR scan is the first listed.
NCT03019029 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03019029 about?
NCT03019029 is a clinical study titled "Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis". The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid disease...
What is the current status of trial NCT03019029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-03-13. Estimated completion is 2022-03-24.
What interventions are being tested in trial NCT03019029?
The interventions under investigation include: 18-F Florbetapir PET/MR scan (OTHER).
Who is sponsoring clinical trial NCT03019029?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03019029's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI